anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing a Prunus persica var. davidiana extract is provided to suppress superoxide generation, to remove free radical, and to ensure antioxidation. CONSTITUTION: A composition for skin whitening contains a Prunus persica var. davidiana extract or a fraction thereof as an active ingredient. The extract is prepared using a solvent which is selected from water, C1-C4 alcohol, and a mixture thereof. The fraction is a methanol fraction, a methylene chloride fraction, an ethyl acetate fraction, or a butanol fraction. The extract or the fraction suppresses tyrosinase activity and melanogenesis without cytotoxicity. [Reference numerals] (AA) Specimen; (BB) Inhibition ratio(%); (CC) Kojic acid; (DD) Hexane fraction; (EE) Methanol extract; (FF) Methylene chloride fraction; (GG) Ethyl acetate fraction; (HH) Butanol fraction
The preliminary theoretical study in which the corneal geometry at different intraocular pressure (IOP) levels is investigated using a theoretical biomechanical cornea model found changes in both conventional refractive error (sphere and cylinder) and irregular astigmatism i.e. higher order aberrations (e.g. spherical aberration, trefoil and quadrafoil). This is due to the mechanical characteristics of the cornea determined largely by interaction between collagen fibrils organization and extrafibrillar matrix material properties. Corneal geometry and the material properties are the two main factors that contribute to the changes in corneal aberrations with IOP elevation. These aberration changes due to the variation of IOP and the material properties of the cornea can be measured routinely with corneal topography systems (UR) and Brillouin ocular scanner (MGH), respectively and can guide the investigators to study their impact on optical and biomechanical behaviors of the cornea.
BACKGROUND: We report the impact of capacity building and teleconsultation on change in the thrombolysis rates and one-year mortality in patients with STEMI using a hub and the spoke model of STEMI care.
METHODS: Twenty secondary care public hospitals were linked with a teaching hospital as a hub centre and the impact of the intervention on change in ischemic time, thrombolysis rates and all-cause in-hospital and one-year mortality was compared.
RESULTS: 29 patients with STEMI were treated during pre-intervention from April 2020 to June 2020 and 255 patients during the post-intervention period from July 2020 to Oct 2021 in spoke centres. 245 patients were reported to a hub centre during the study period. The thrombolysis rate was significantly higher in the spoke centres after intervention (65.5%vs. 27.5 % p < 0.001) and was also significantly higher than in patients treated in a hub centre (65.5 % vs. 45.7 % p < 0.01). The in-hospital mortality was significantly lower in patients treated at spoke centres compared to those treated at the hub centre (7.8 % vs. 15.5 % < 0.003). The significant difference in mortality rate continued at one year (11.0 % vs.18.4 % p < 0.01). The median time from symptoms to thrombolytic therapy was significantly lower in STEMI patients treated in spoke centres compared to a hub centre (230 min vs. 356 min p < 0.001).
CONCLUSION: The hub and spoke model of STEMI care is effective in increasing thrombolysis rate, and decreasing in-hospital and one-year mortality rate.
Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.
PURPOSE:To provide a pain mitigating agent for renal osteodystrophy, containing 24,25-dihydroxycholecalciferol as an active component, having high safety, and applicable for a long period. CONSTITUTION:24,25-Dihydroxycholecalciferol, preferably 24R,25- dihydroxycholecalciferol is used as a pain mitigating agent for renal osteodystrophy (ROD). Dose: 0.1-100,000mug, preferably 0.5-10,000mug daily for adult. It has been found that 24,25-dihydroxycholecalciferol is effective to mitigate the pain in ROD, i.e. is remarkably effective to a complication. It has extremely high safety. It is administered preferably by oral administration.
To compare the clinical efficacy of interlaminar endoscopic surgical system delta (iLESSYS-Delta) discectomy with that of classical fenestration discectomy for treating lumbar disc herniation. Patients who underwent iLESSYS-Delta or fenestration discectomy were enrolled in this study. Baseline information and clinical indicators were collected. The baseline data were matched using propensity score matching. Fifty-two patients were in each group. In the iLESSYS-Delta cohort, the volume of intraoperative bleeding was 18.17 ± 4.20 ml, the length of postoperative hospital stay was 4.16 ± 2.29 days, and the length of postoperative off-bed activity was 1.58 ± 0.88 days. In contrast, in the fenestration group, the volume of intraoperative bleeding was 32.50 ± 17.13 ml, the length of postoperative hospital stay was 6.66 ± 2.44 days, and the length of postoperative off-bed activity was 3.18 ± 1.28 days. The difference between the two groups was statistically significant (P < 0.05). The operation time was 88.90 ± 19.14 min in the iLESSYS-Delta group and 67.63 ± 19.32 min in the fenestration group, and the difference between the two groups was statistically significant (P < 0.05). Regarding the pain visual analogue scale scores at 24, 48, and 72 h after surgery, patients in the iLESSYS-Delta group had less pain than did those in the fenestration group (P < 0.05). The Oswestry disability indices of postoperative patients in both groups significantly improved at 3 months after surgery and at the last follow-up (P < 0.05); however, there was no statistically significant difference in the postoperative ODI scores between the two surgery groups (P > 0.05). The two groups showed no significant differences in clinical effects, postoperative recurrence rates, or perioperative complications. iLESSYS-Delta can cause less intraoperative bleeding and faster recovery than fenestration discectomy.
All patients will receive an individualized ten sessions of an in-hospital rehabilitation program (1 hour/day, 3 days/week) by a qualified physiotherapist at each participating unit. Then, the EG will follow a 12-week individualized Digital Telerehabilitation program (1 hour/day, 3 days/week, EG).
Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
Growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor, is an important nutrient sensor and metabolic regulator in both humans and rodents. Increased GHS-R1a expression is observed in the hippocampus of both Alzheimer's disease (AD) patients and AD model mice. However, the causal relationship between GHS-R1a elevation in the hippocampus and AD memory deficits remains uncertain. Here, we find that increasing GHS-R1a expression in dCA1 pyramidal neurons impairs hippocampus-dependent memory formation, which is abolished by local administration of the endogenous antagonist LEAP2. GHS-R1a elevation in dCA1 pyramidal neurons suppresses excitability and blocks memory allocation in these neurons. Chemogenetic activation of those high GHS-R1a neurons during training rescues GHS-R1a overexpression-induced memory impairment. Moreover, we demonstrate that increasing GHS-R1a expression in dCA1 pyramidal neurons hampers these neurons' ability to encode spatial memory and reduces engram size in the dCA1 region. Finally, we show that GHS-R1a deletion mitigates spatial memory deficits in APP/PS1 mice with increased GHS-R1a expression in the hippocampus. Our findings reveal a negative, causal relationship between hippocampal GHS-R1a expression and memory encoding, and suggest that blocking the abnormal increase in GHS-R1a activity/expression may be a promising approach to improve memory and treat cognitive decline in AD.
The invention discloses a traditional Chinese medicine composition for treating subdural hematoma and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 30-60 parts of motherwort herb, 9-20 parts of peach kernel, 9-20 parts of safflower and 3-6 parts of leech. The Chinese medicinal composition can be prepared into any oral preparation according to a conventional Chinese medicinal preparation method. In order to facilitate dispensing and avoid decoction, each Chinese medicinal material (such as Chinese medicinal decoction pieces) can be replaced by commercially available Chinese medicinal granule with equivalent crude drug amount, and the Chinese medicinal granule of each Chinese medicinal material can be directly mixed. It is administered by soaking in boiled water. Clinical researches prove that the recipe can promote the absorption of the subdural hematoma, improve the neurological deficit symptom of a patient, improve the life quality of the patient, reduce the recurrence, reduce the operation risk and the economic burden of the patient, become the beneficial choice of a small amount of acute/subacute subdural hematoma patients with chronic subdural hematoma and stable illness state, especially the aged chronic subdural hematoma patients, and has great economic benefit and social benefit.
The present invention relates to attenuated salmonella and its use in treating tumors. The present invention belongs to biological technique field. The present invention discloses the constructions of pH1Si-Stat3, pGRIM-19, and pGRIM-19-Si-Stat3 recombinant plasmid, which coexpresses GRIM-19 and siRNA-Stat3. An attenuation salmonella electrotransformated with the recombinant plasmid is disclosed. The coexpression of GRIM-19 and siRNA-Stat3 has a good synergistic inhibition effect on the growth and metastases of tumors in the experiment in vivo. Attenuated salmonella has phagorytosis effect on tumors, and the progenitive specificity in tumortissue is more than 1000 times as that in normal tissue. The attenuated salmonella carrying effective plasmid, which can coexpresses siRNA-Stat3 and GRIM-19, can reach the deep part of tumors, and thus markedly inhibit their growth and metastases and evidently prolong the survival time of mice.
The present invention provides an apparatus for evaluating a drug effect enabling on-chip evaluation of the effect of a drug while the drug is acting on hERG-expressing cells. The present invention also provides a myocardial toxicity test apparatus and method therefor enabling in vitro myocardial toxicity testing that has previously been performed in vivo. A pulsating cell population and hERG-expressing cells (target model cells) are suitably isolated and arranged on a transparent substrate so that the two form gap junctions. The hERG-expressing cells are arranged on transparent electrodes provided on the transparent substrate. The hERG-expressing cells are exposed to a flow of a liquid containing a drug such that the drug acts thereon. The difference between the normal pulsation of hERG-expressing cells and the pulsation when a drug is acting thereon is captured via electric signals obtained from electrodes, and the properties of the change in potential are evaluated.
<P>PROBLEM TO BE SOLVED: To provide a method for producing tablets and device for the same, performing the discharge of the tablets by surely preventing the tablets from the attachment or peeling with a pushing-out pin and further producing the tablets in good accuracy and in a good efficiency by making its constitution as simple one.  <P>SOLUTION: This tablet X having a prescribed form is formed by filling a wet powdery material in a mold cavity 4 of a platy table 2 and compressing from upper and lower directions. A releasing agent layer Z is installed on the tablet X in the mold cavity 4 by feeding the releasing agent Y consisting of a dried powdery material on the tablet X in the mold cavity. By inserting a pushing-out pin 25 from an upper open end of the mold cavity 4, the tablet X in the mold cavity 4 is pushed out through the releasing agent layer Z toward the lower direction of the table 2 for discharging. The attachment of the tablet X with the pushing-out pin 25 is prevented by the releasing agent layer Z.  <P>COPYRIGHT: (C)2008,JPO&INPIT
GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
BACKGROUND: To compare kidney blood flow and kidney function tests in infants with hypoxic ischemic encephalopathy (HIE), and the effects of therapeutic hypothermia (TH) during the first 7 days of life.
METHODS: Fifty-nine infants with HIE were prospectively evaluated. Infants with moderate-severe HIE who required TH were classified as group 1 (n = 36), infants with mild HIE were classified as group 2 (n = 23), and healthy infants were classified as group 3 (n = 60). Kidney function tests were evaluated on the sixth hour, third and seventh days of life in Group 1 and Group 2, and on the sixth hour and third day of life in group 3. Renal artery (RA) Doppler ultrasonography (dUS) was performed in all infants on the first, third, and seventh days of life.
RESULTS: Systolic and end diastolic blood flow in RA tended to increase and RA resistive index (RI) tended to decrease with time in group 1 (p = 0.0001). While end diastolic blood flow rates in RA on the third day were similar in patients with severe HIE and mild HIE, it was lower in patients with mild-moderate-severe HIE than healthy newborns. On the seventh day, all three groups had similar values (p > 0.05). Serum blood urea nitrogen (BUN), creatinine, uric acid, and cystatin C levels gradually decreased and glomerular filtration rate (GFR) gradually increased during TH in group 1 (p = 0.0001). Serum creatinine levels gradually decreased while GFR gradually increased during the study period in group 2.
CONCLUSIONS: Therapeutic hypothermia seems to help restore renal blood flow and kidney functions during the neonatal adaptive period with its neuroprotective properties.
BACKGROUND: Lung cancer (LC), a paramount global life-threatening condition causing significant mortality, is most commonly characterized by its subtype, lung adenocarcinoma (LUAD). Concomitant with LC, pulmonary fibrosis (PF) and interstitial lung disease (ILD) contribute to an intricate landscape of respiratory diseases. Idiopathic pulmonary fibrosis (IPF) in association with LC has been explored. However, other fibrotic interrelations remain underrepresented, especially for LUAD-PF and LUAD-ILD.
METHODS: We analysed data with statistical analysis from 7,137 healthy individuals, 7,762 LUAD patients, 7,955 ILD patients, and 2,124 complex PF patients collected over ten years. Furthermore, to identify blood indicators related to lung disease and its complications and compare the relationships between different indicators and lung diseases, we successfully applied the naive Bayes model for a biomarker-based prediction of diagnosis and development into complex PF.
RESULTS: Males predominantly marked their presence in all categories, save for complex PF where females took precedence. Biomarkers, specifically AGR, MLR, NLR, and PLR emerged as pivotal in discerning lung diseases. A machine-learning-driven predictive model underscored the efficacy of these markers in early detection and diagnosis, with NLR exhibiting unparalleled accuracy.
CONCLUSIONS: Our study elucidates the gender disparities in lung diseases and illuminates the profound potential of serum biomarkers, including AGR, MLR, NLR, and PLR in early lung cancer detection. With NLR as a standout, therefore, this study advances the exploration of indicator changes and predictions in patients with pulmonary disease and fibrosis, thereby improving early diagnosis, treatment, survival rate, and patient prognosis.
Cotrimoxazole (Trimethoprim/Sulfamethoxazole-SMX) is frequently used in critically ill and immunocompromised patients. SMX is converted to N-acetyl-sulfamethoxazole (NASM) and excreted by the kidneys. NASM may form crystals in urine, especially in acid urine, that may induce a crystalline nephropathy. However, the imputability of crystals in acute kidney injury (AKI) has not been proven. We aimed to assess whether NASM crystals may promote AKI and to investigate risk factors associated with NASM crystalline nephropathy. Patients from Ile-de-France, France who developed AKI under SMX treatment introduced during hospitalization and had a crystalluria positive for NASM crystals were selected. Patients with excessive preanalytical delay for crystalluria or missing data regarding SMX treatment were excluded. We used the Naranjo score to assess the causal relationship between SMX and the development of AKI in patients with positive NASM crystalluria. Fourteen patients were included. SMX was the probable cause of AKI for 11 patients and a possible cause for 3 patients according to Naranjo score. Patients were exposed to high doses of SMX (but within recommended ranges), and most of them had a preexisting chronic kidney disease and were hypoalbuminemic. Urine pH was mildly acid (median 5.9). AKI occured more rapidly than expected after introduction of SMX (median 4 days) and recovered rapidly after drug discontinuation in most, but not all, cases. SMX is a probable cause of crystalline nephropathy. Monitoring of crystalluria in patients exposed to SMX may be of interest to prevent the development of crystalline nephropathy. Approval number of the study: BPD-2018-DIAG-008.
BACKGROUND: Biliary atresia (BA) is a devastating congenital disease characterized by inflammation and progressive liver fibrosis. Activation of hepatic stellate cells (HSCs) plays a central role in the pathogenesis of hepatic fibrosis. Our study aimed to investigate the pharmacological effect and potential mechanism of pirfenidone (PFD) and andrographolide (AGP) separately and together on liver fibrosis of BA.
MATERIALS AND METHODS: The bile ducts of male C57BL/6J mice were ligated or had the sham operation. The in vivo effects of PFD and/or AGP on liver fibrosis of BA were evaluated. Human hepatic stellate cells (LX-2) were also treated with PFD and/or AGP in vitro.
RESULTS: PFD and/or AGP ameliorates liver fibrosis and inflammation in the mice model of BA, as evidenced by significant downregulated in the accumulation of collagen fibers, hepatic fibrosis markers (α-SMA, collagen I, and collagen IV), and inflammatory markers (IL-1β, IL-6, and TNF-α). Moreover, compared with monotherapy, these changes are more obvious in the combined treatment of PFD and AGP. Consistent with animal experiments, hepatic fibrosis markers (α-SMA, collagen I, and CTGF) and inflammatory markers (IL-1β, IL-6, and TNF-α) were significantly decreased in activated LX-2 cells after PFD and/or AGP treatment. In addition, PFD and/or AGP inhibited the activation of HSCs by blocking the TGF-β/Smad signaling pathway, and the combined treatment of PFD and AGP synergistically inhibited the phosphorylation of Smad2 and Smad3.
CONCLUSION: The combined application of PFD and AGP exerted superior inhibitive effects on HSC activation and liver fibrosis by mediating the TGF-β/Smad signaling pathway as compared to monotherapy. Therefore, the combination of PFD and AGP may be a promising treatment strategy for liver fibrosis in BA.
A parenteral pharmaceutical composition comprising azacitidine and dimethyl sulfoxide, wherein the pharmaceutical composition comprises azacitidine at a concentration of from 40 mg/mL to 340 mg/mL. An injection syringe, a cartridge, a container or a vial containing the pharmaceutical composition for single or multiple dosing. The pharmaceutical composition for use in the treatment of myelodysplastic syndrome, acute myelomonocytic leukemia or chronic myelomonocytic leukemia. A kit of parts comprising the pharmaceutical composition in a vial, cartridge or container and an injection device. A method for preparing the pharmaceutical composition comprising the steps of (a) providing azacitidine or decitabine; and (b) mixing the azacitidine or the decitabine with dimethyl sulfoxide to provide the pharmaceutical composition. An infusion composition obtainable by mixing the pharmaceutical composition and an infusion solution.
The invention relates to a pharmaceutical formulation for treating psoriasis. The pharmaceutical formulation is prepared by mixing the following components of: alcohol, salicylic acid, benzoic acid, penicillin and rivanol. The treatment course of the pharmaceutical formulation is short and usually lasts for 3-5 days. The medicine is an externally applied medicine which is wiped on affected areas for one to two treatment courses. The cure rate of the medicine reaches more than 90%, and radical cured patients reach 85%. The medicine is safe to use, and has no toxic or side effect.
PURPOSE:To prepare a pharmaceutical adhesive plaster having suppressed decomposition of the drug component and improved stability, by compounding tocopherol to a plaster base composed of an acrylic adhesive substance. CONSTITUTION:The objective plaster is obtained by compounding a plaster base composed of an acrylic adhesive substance (e.g. n-butyl methacrylate) with one or more tocopherols (e.g. alpha-tocopherol). The application of a drug component to the skin is carried out usually by the use of a pharmaceutical adhesive plaster obtained e.g. by compounding the drug component to a plaster composed of an adhesive substance. When a pharmaceutical preparation obtained by compounding a drug, especially a compound containing phenolic OH-group or an amine compound to a plaster composed of an acrylic adhesive substance is stored for a long period, the remedying effect is remarkably decreased by the decomposition and dissipation of the drug component. The decomposition of the drug can be suppressed by compounding tocopherols to the plaster. The amount of tocopherol added to the acrylic adhesive is about 0.005-5wt%.
Children conceived through assisted reproductive technologies (ART) have an elevated risk of lower birthweight, yet the underlying cause remains unclear. Our study explores mitochondrial DNA (mtDNA) variants as contributors to birthweight differences by impacting mitochondrial function during prenatal development. We deep-sequenced the mtDNA of 451 ART and spontaneously conceived (SC) individuals, 157 mother-child pairs and 113 individual oocytes from either natural menstrual cycles or after ovarian stimulation (OS) and find that ART individuals carried a different mtDNA genotype than SC individuals, with more de novo non-synonymous variants. These variants, along with rRNA variants, correlate with lower birthweight percentiles, independent of conception mode. Their higher occurrence in ART individuals stems from de novo mutagenesis associated with maternal aging and OS-induced oocyte cohort size. Future research will establish the long-term health consequences of these changes and how these findings will impact the clinical practice and patient counselling in the future.
Disclosed are systems and methods for integrating data and compliance monitoring. Certain embodiments provide a method includes loading an application programming interface preselected to generate a query. The query is sent via a network to a database requesting data for a patient. The data for the patient is received from the database via the network. The data associated is stored with the patient in a compliance database. The data for the patient is compared to a rule set to determine a compliance measurement. An output that includes the compliance measurement is generated.